Αρχική World News Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node Micrometastases...

Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node Micrometastases the Morbidity of Lymphadenectomy

Inguinofemoral radiotherapy for patients with vulvar cancer and micrometastases in the sentinel node is safe alternative for inguinofemoral lymphadenectomy according to the GROINSS-V-II study investigators. The radiotherapy side effects were acceptable with less frequent treatment-related morbidity compared with inguinofemoral lymphadenectomy. However, in patients with sentinel node macrometastases, radiotherapy with a total dose of 50 Gy showed more isolated groin recurrences than inguinofemoral lymphadenectomy. The findings of the GROINSS-V-II study are published by Dr. Maaike H.M. Oonk of the University Medical Centre Groningen, University of Groningen in Groningen, the Netherlands and colleagues on 25 August 2021 in the Journal of Clinical Oncology.

The authors explained in the study background that the treatment for early-stage vulvar cancer has undergone major advances in the past years with introduction of the sentinel node procedure representing one of the major advances in vulvar cancer treatment. The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-I showed that inguinofemoral lymphadenectomy could be safely omitted in patients with negative sentinel node, resulting in significant decrease of morbidity. Patients with metastases in sentinel node currently need to undergo lymphadenectomy and suffer from morbidity of this treatment.

The primary aim of the GROINSS-V-II study was to establish whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy in patients with vulvar cancer and metastatic sentinel node. The secondary aim was to establish the short- and long-term treatment-related morbidity for this management strategy. The study provided the opportunity to collect further data on the safety of omitting inguinofemoral lymphadenectomy in patients with a negative sentinel node. Stopping rules were defined for the occurrence of groin recurrences.

The GROINSS-V-II was a prospective multicentre phase II single-arm study that included patients with early-stage vulvar cancer (diameter <4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment of local excision with sentinel node biopsy. If the sentinel node was involved (metastasis of any size), inguinofemoral radiotherapy of 50 Gy was delivered. The study primary endpoint was isolated groin recurrence rate at 24 months.

From December 2005 to October 2016, the study investigators registered 1,535 eligible patients from whom 322 patients (21.0%) had metastasis in the sentinel node. In June 2010, with 91 included patients with positive sentinel node, the stopping rule was activated because the isolated groin recurrence rate in this group was above predefined threshold.

Among 10 patients with an isolated groin recurrence, 9 had sentinel node metastases >2 mm and/or extracapsular spread. The protocol was amended so that those with sentinel node macrometastases (>2 mm) underwent inguinofemoral lymphadenectomy as a standard of care, whereas patients with sentinel node micrometastases (≤2 mm) continued to receive inguinofemoral radiotherapy.

Among 160 patients with sentinel node micrometastases, 126 received inguinofemoral radiotherapy, with 1.6% of an ipsilateral isolated groin recurrence rate at 2 years. Among 162 patients with sentinel node macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent inguinofemoral lymphadenectomy (p = 0.011).

Treatment-related morbidity after radiotherapy was less frequent compared with inguinofemoral lymphadenectomy.

The authors concluded that in the GROINSS-V-II study, radiotherapy showed to be similarly safe as compared to GROINSS-V-I data in terms of groin recurrence rate for patients with sentinel node micrometastases. The morbidity of inguinofemoral radiotherapy was less compared with lymphadenectomy. However, for patients with sentinel node macrometastases, the recurrence rate was higher with radiotherapy. For them, standard therapy remains lymphadenectomy, and further research is needed. Radiotherapy dose escalation in combination with chemotherapy will be investigated for such patients in GROINSS-V-III.

The authors commented that inguinofemoral radiotherapy could spare patients with vulvar cancer and sentinel node micrometastases the morbidity of lymphadenectomy and advocated to implement this in (inter)national treatment guidelines for vulvar cancer.

The study was supported by the Dutch Cancer Society (KWF Kankerbestrijding), NRG Oncology.

Reference

Oonk MHM, Slomovitz B, Baldwin PJW, et al. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. JCO; Published online 25 August 2021. DOI: 10.1200/JCO.21.00006.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...